CCIA
TARA icon

Campbell & Co Investment Adviser’s Protara Therapeutics TARA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,551
Closed -$110K – 1416
2025
Q4 		$110K Buy
+20,551
New +$114K 0.01% 1087

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Campbell & Co Investment Adviser's TARA Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Protara Therapeutics (TARA) in Q1 2026, closing a stake of 20,551 shares — an estimated $110K sold.

Campbell & Co Investment Adviser first reported a position in TARA in Q4 2025 and held it in 1 quarter. The position peaked at $110K in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Protara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 20,551 Protara Therapeutics shares in Q1 2026, an estimated $110K.
  • Campbell & Co Investment Adviser first reported a position in Protara Therapeutics in Q4 2025 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Protara Therapeutics position peaked at $110K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.